Finch Therapeutics Group, Inc. (FNCH) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
75 STATE STREET BOSTON, MA 02109 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2023 MRQ | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 71,038 | 133,481 | |||
| Cash and cash equivalents | 71,038 | 133,481 | |||
| Receivables | 144 | 494 | |||
| Other undisclosed current assets | 3,369 | 8,576 | |||
| Total current assets: | 74,551 | 142,551 | |||
| Noncurrent Assets | |||||
| Finance lease, right-of-use asset, after accumulated amortization | 1 | 22 | |||
| Operating lease, right-of-use asset | 32,752 | 5,053 | |||
| Property, plant and equipment | 15,936 | 19,635 | |||
| Intangible assets, net (including goodwill) | 18,057 | ||||
| Goodwill | 18,057 | ||||
| Restricted cash and investments | 2,568 | 2,268 | |||
| Other noncurrent assets | 4,232 | 4,905 | |||
| Other undisclosed noncurrent assets | 32,899 | 32,878 | |||
| Total noncurrent assets: | 88,388 | 82,818 | |||
| TOTAL ASSETS: | 162,939 | 225,369 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 9,291 | 12,317 | |||
| Employee-related liabilities | ✕ | ✕ | 4,401 | ||
| Accounts payable | 1,097 | 3,737 | |||
| Accrued liabilities | 8,194 | 4,179 | |||
| Debt | 6 | 19 | |||
| Other undisclosed current liabilities | 5,392 | 2,454 | |||
| Total current liabilities: | 14,689 | 14,790 | |||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 14,653 | 4,887 | |||
| Long-term debt, excluding current maturities | 14,653 | ||||
| Liabilities, other than long-term debt | 37,886 | 3,468 | |||
| Deferred income tax liabilities | 3,461 | 3,461 | |||
| Other liabilities | 170 | 7 | |||
| Operating lease, liability | 34,255 | 4,887 | |||
| Total noncurrent liabilities: | 52,539 | 8,355 | |||
| Total liabilities: | 67,228 | 23,145 | |||
| Equity | |||||
| Equity, attributable to parent | 95,711 | 202,224 | |||
| Common stock | 48 | 47 | |||
| Additional paid in capital | 371,304 | 363,172 | |||
| Accumulated deficit | (275,641) | (160,995) | |||
| Total equity: | 95,711 | 202,224 | |||
| TOTAL LIABILITIES AND EQUITY: | 162,939 | 225,369 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Revenues | 861 | 18,532 | ||
| Sublease income | 702 | 88 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (5,000) | |||
| Other undisclosed gross profit | ||||
| Gross profit: | (4,139) | 18,532 | ||
| Operating expenses | (116,454) | (78,517) | ||
| Other undisclosed operating income | 5,000 | |||
| Operating loss: | (115,593) | (59,985) | ||
| Nonoperating income | 947 | 1,825 | ||
| Investment income, nonoperating | 252 | 22 | ||
| Other nonoperating income (expense) | 702 | (52) | ||
| Interest and debt expense | (4) | 1,808 | ||
| Loss from continuing operations before equity method investments, income taxes: | (114,650) | (56,352) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 4 | (1,808) | ||
| Loss from continuing operations before income taxes: | (114,646) | (58,160) | ||
| Income tax benefit | ||||
| Loss from continuing operations: | (114,646) | (58,160) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (58,160) | |
| Net loss available to common stockholders, diluted: | (114,646) | (58,160) | ||
Comprehensive Income ($ in thousands)
| 9/30/2023 TTM | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|
| Net loss: | (114,646) | (58,160) | ||
| Comprehensive loss, net of tax, attributable to parent: | (114,646) | (58,160) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.